about
Degradation of mutant p53H175 protein by Zn(II) through autophagy.Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of functionLeptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cellsPKC theta ablation improves healing in a mouse model of muscular dystrophy.In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancerChe-1-induced inhibition of mTOR pathway enables stress-induced autophagy.Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals.The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cellsTargeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status.Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation.MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells.HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy.Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression.Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer.Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy.Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.CorrigendumCytokine Modulation in Breast Cancer Patients Undergoing Radiotherapy: A Revision of the Most Recent StudiesSer58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosisMKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancerThe p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic TreatmentsApproaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer
P50
Q33709136-57732D30-8AA1-4462-BDB0-35C5B5B9B730Q33825046-CD7134F8-8E03-42C3-B8BD-0ED3BE12E4EEQ34010406-FAFC7731-3B92-401E-8876-688C4DAE3A72Q34163572-BE3A2153-349A-4907-9C55-0C95F447D7C7Q35168034-133DC68F-8F0D-44DB-AC81-6752BF3A09D6Q35590396-06FE0DCB-2AA5-4D87-B3B5-788A5DAD4265Q35891239-D6CF70E7-6E72-40B5-A13C-5C6DEB968748Q35986990-19D49802-D9CC-4756-ADDE-6CE65D0CCE99Q36347205-A1D85E2F-1A71-4F68-9DF4-E536567AC57AQ36525180-FF39F5F4-9ACF-422E-BBAB-6F12D522C0B6Q36710840-E785D195-8B10-4E88-AB9B-B12E5F3C01C0Q38977664-378633D8-AE9D-4CD7-8DB8-C355C6DEF87CQ39042161-8B6582CA-EC9F-4173-8A60-53CF9065A65FQ39667788-296EF91B-3849-4DB9-A101-34576EA2628AQ39877577-00D37F55-4516-42BD-9B12-1BF45DC1D072Q39919668-1C1E79B3-BAE0-450B-84BD-BB7C2FF7C250Q39961155-8370951A-2C0E-4DED-8B47-5AB3534698C7Q41007292-83535568-E9C5-41A4-B47C-D643755AFF33Q42288961-483D4C09-EF91-45F4-96E2-38B615382BCDQ45871670-11BF0D93-1689-42DE-AE9D-168CF0BD9DA0Q51757944-AB6CBF96-B0C2-454D-878B-418D0C164936Q54110522-A5706E7A-EBF3-476E-9D35-8373508B5207Q54473491-1712E282-6C42-47D4-9A94-A52954DE0215Q55026448-814B4B5D-CE00-488F-ABCF-D25221B91252Q60393612-264CFCBE-33CF-4C7C-9B6E-22175C4C85DDQ61814437-FBF48DE9-1161-4AE6-B331-43AD936A1A25Q83855474-76B7DA76-08AC-4B00-BAB2-F209F80C63A4Q91151365-1F3B7AA4-C764-4184-933E-DE21A131ECFFQ92121511-A5C99807-C860-4649-B8CB-459A81C91763Q92283453-7B458EEF-2E95-485C-8D0A-401892E3391D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gianluca Bossi
@ast
Gianluca Bossi
@en
Gianluca Bossi
@es
Gianluca Bossi
@nl
Gianluca Bossi
@sl
type
label
Gianluca Bossi
@ast
Gianluca Bossi
@en
Gianluca Bossi
@es
Gianluca Bossi
@nl
Gianluca Bossi
@sl
prefLabel
Gianluca Bossi
@ast
Gianluca Bossi
@en
Gianluca Bossi
@es
Gianluca Bossi
@nl
Gianluca Bossi
@sl
P1053
G-8375-2016
P106
P1153
14017700600
P21
P31
P3829
P496
0000-0002-2947-1063